We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Test Detects Sepsis Earlier

By LabMedica International staff writers
Posted on 25 Sep 2012
A single automated test provides fast genus and species level detection for a broad panel of clinically significant Gram-positive bacteria.

The test also detects several crucial markers for antimicrobial resistance, including the genes, which confer resistance to the antibiotics methicillin/oxacillin and vancomycin, and rapid detection of these antimicrobial resistance markers provides vital information for clinicians to determine the best treatment for bloodstream infections.

The first-ever diagnostic tool for detecting disease-causing bacteria while simultaneously determining antibiotic resistance is known as the Verigene Gram-positive Blood Culture Nucleic Acid Test (BC-GP). It has been approved by the US Food and Drug Administration (FDA; Silver Springs, MD, USA). The BC-GP test provides identification of bacteria and antimicrobial resistance genes from Gram-positive blood culture bottles within two and a half hours, as compared with current microbiological methods, which can take up to two to three days.

The sample-to-result BC-GP test automates the steps of bacterial DNA extraction and target detection on the Verigene System, which is produced by Nanosphere (Northbrook, IL, USA). The ease-of-use and fast turnaround time of the BC-GP test allow hospitals of any size to benefit from the speed and accuracy of automated molecular testing. In addition to its Gram-positive blood culture test, Nanosphere is currently developing a test for Gram-negative blood cultures that will provide genus, species, and resistance detection on the same automated platform.

William Moffitt, BS, president and CEO of Nanosphere, said, "The test works by mapping the genome of a particular bacterium and capturing it on a glass slide. If that bacterium is present in the blood sample, it will bind to the material on the slide. Then the test uses silver-coated gold nanoparticles to bind to the captured genetic sequence. When light is shined on the slide, if the spots light up, it means the bug is present in the sample."

Related Links:

US Food and Drug Administration
Nanosphere



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Portable Electronic Pipette
Mini 96
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
New
Human Estradiol Assay
Human Estradiol CLIA Kit

Latest Microbiology News

Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
25 Sep 2012  |   Microbiology

New Diagnostic Method Confirms Sepsis Infections Earlier
25 Sep 2012  |   Microbiology

New Markers Could Predict Risk of Severe Chlamydia Infection
25 Sep 2012  |   Microbiology